AstraZeneca to build $2.5B research hub in Beijing
AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational ...
AstraZeneca boosts cancer therapies push with $1 billion EsoBiotec buy
Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, ...
Fierce Biotech1d
AstraZeneca details $2.5B investment in China's political center, funding R&D center, biotech pacts
Tallying up a wide range of investments, AstraZeneca said it is pumping $2.5 billion into Beijing. The figure includes ...
AstraZeneca to invest $2.5 billion in Beijing hub as it seeks to move on from China probes
British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development ...
AstraZeneca invests $2.5 billion in Beijing hub amid probe
AstraZeneca Plc will invest $2.5 billion in a new research center in Beijing, in a major show of commitment to China just ...
AstraZeneca (AZN) Invests $2.5B in China R&D Hub
AstraZeneca (AZN) said Friday it plans to invest $2.5 billion in a new research and development hub in China as the drugmaker tries to reignite ...
Anadolu Agency1d
AstraZeneca invests $2.5B in China for R&D, biotech partnerships
This $2.5 billion investment reflects AstraZeneca's belief in "the world-class life sciences ecosystem in Beijing" and its ...
Fierce Pharma1d
Fierce Pharma Asia—AstraZeneca-Alteogen drug delivery deal; Taiho's ADC buyout; WuXi's rosy 2025 outlook
AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...